Author

Chan Cheah

Observed name: Cheah, Chan Y.

Institutions: The University of Western Australia, Hollywood Private Hospital, Sir Charles Gairdner Hospital

Observed institutions: The University of Western Australia, Hollywood Private Hospital, Sir Charles Gairdner Hospital

OpenAlex ID: A5136304102

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

2025 · Michael Wang, Michael Wang, et al. · Journal of Clinical Oncology · 67

frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

2026 · Georg Lenz, Marek Trněný, et al. · Journal of Clinical Oncology · 2

Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.

2026 · Yasmin Karimi, Pau Abrisqueta, et al. · Journal of Clinical Oncology · 1

Effect of first-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) on minimal residual disease (uMRD) rates, including in patients with del(17p)/TP53.

2026 · Constantine Si Lun Tam, Stephen Opat, et al. · Journal of Clinical Oncology

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B‐cell lymphoma limits applicability to clinical practice

2026 · Elizabeth Goodall, Jodie Palmer, et al. · British Journal of Haematology

Works count: 6

Citation count: 69

H-index: 2

I10-index: 1